Similar articles

• High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.

  Kjaer M, Frederiksen PL. Kjaer M, et al. Cancer Treat Rep. 1986 Mar;70(3):431-2. Cancer Treat Rep. 1986. PMID: 2937534 No abstract available.
• Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma.

  Tomić R, Ljungberg B, Damber JE. Tomić R, et al. Scand J Urol Nephrol. 1988;22(1):15-8. doi: 10.1080/00365599.1988.11690377. Scand J Urol Nephrol. 1988. PMID: 2968646
• Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.

  Nilsson TK, Tomic R, Ljungberg B. Nilsson TK, et al. Scand J Urol Nephrol. 1989;23(1):11-4. doi: 10.1080/00365599.1989.11690424. Scand J Urol Nephrol. 1989. PMID: 2522237
• An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.

  Robustelli della Cuna G, Zanon P, Pavesi L, Preti P, Prada GA, Decensi A. Robustelli della Cuna G, et al. Chemioterapia. 1986 Jun;5(3):164-72. Chemioterapia. 1986. PMID: 2941173 Review.
• The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.

  Kjaer M. Kjaer M. Cancer Treat Rev. 1988 Sep;15(3):195-209. doi: 10.1016/0305-7372(88)90003-5. Cancer Treat Rev. 1988. PMID: 2974757 Review. No abstract available.